Published on 3 Aug 2023 on Zacks via Yahoo Finance
Avalo Therapeutics, Inc. (AVTX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.38 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 34.44%. A quarter ago, it was expected that this company would post a loss of $0.97 per share when it actually produced a loss of $0.85, delivering a surprise of 12.37%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.